PDF herunterladen
CC BY 4.0 · Arq Neuropsiquiatr 2022; 80(09): 953-969
DOI: 10.1055/s-0042-1755320
Brazilian Academy of Neurology

Consensus of the Brazilian Headache Society (SBCe) for prophylactic treatment of episodic migraine: part II

Consenso da Sociedade Brasileira de Cefaleia (SBCe) para o tratamento profilático da migrânea episódica: parte II
Paulo Sergio Faro Santos 
1   Instituto de Neurologia de Curitiba, Departamento de Neurologia, Setor de Cefaleia e Dor Orofacial, Curitiba PR, Brazil.
,
Eliana Meire Melhado 
2   Centro Universitário Padre Albino, Faculdade de Medicina, Departamento de Neurologia, Catanduva SP, Brazil.
,
Alexandre Ottoni Kaup 
3   Houston Headache Clinic, Houston TX, USA.
4   Universidade Federal de São Paulo, São Paulo SP, Brazil.
5   Universidade de Santo Amaro, São Paulo SP, Brazil.
,
Aline Turbino Neves Martins da Costa 
6   Hospital Santa Marcelina , São Paulo SP, Brazil.
,
Célia Aparecida de Paula Roesler 
7   Centro Médico de Neurologia, São Paulo SP, Brazil.
,
Élcio Juliato Piovesan 
8   Universidade Federal do Paraná, Departamento de Clínica Médica, Disciplina de Neurologia, Curitiba PR, Brazil.
,
Elder Machado Sarmento 
9   Universidade Federal Fluminense, Rio de Janeiro RJ, Brazil.
,
Giselle Oliveira Martins Theotonio 
10   Universidade Federal do Rio de Janeiro, Centro de Pesquisas Rene Rachou, Editora UFRJ, Rio de Janeiro RJ, Brazil.
,
Henrique Carneiro de Campos 
11   Clínica Neurológica, Belo Horizonte MG, Brazil.
,
Ida Fortini 
12   Universidade de São Paulo, Faculdade de Medicina, Departamento de Neurologia, São Paulo SP, Brazil.
,
Jano Alves de Souza 
13   Universidade Federal Fluminense, Departamento de Medicina Clínica, Disciplina de Neurologia, Niterói RJ, Brazil.
,
Jayme Antunes Maciel Júnior 
14   Universidade Estadual de Campinas, Faculdade de Ciências Médicas, Departamento de Neurologia, Campinas SP, Brazil.
,
João Batista Alves Segundo 
15   Centro Integrado de Saúde Lineu Araújo, Ambulatório de Neurologia, Teresina PI, Brazil.
,
João José Freitas de Carvalho 
16   Unichristus, Curso de Medicina, Disciplina de Neurologia, Fortaleza CE, Brazil.
17   Hospital Geral de Fortaleza, Serviço de Neurologia, Núcleo de Cefaleias, Fortaleza CE, Brazil.
,
José Geraldo Speziali 
18   Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Neurologia, Ribeirão Preto SP, Brazil.
,
Leandro Cortoni Calia 
19   Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo SP, Brazil.
,
Liselotte Menke Barea 
20   Fundação Universidade Federal de Ciências da Saúde de Porto Alegre, Disciplina de Neurologia, Porto Alegre RS, Brazil.
,
Luiz Paulo Queiroz 
21   Universidade Federal de Santa Catarina, Hospital Universitário, Serviço de Neurologia, Florianópolis SC, Brazil.
,
Marcio Nattan Portes Souza 
22   Universidade de São Paulo, Hospital das Clínicas, São Paulo SP, Brazil.
,
Marcos Ravi Cerqueira Ferreira Figueiredo 
23   Hospital Universitário Antônio Pedro, Serviço de Neurologia, Niterói RJ, Brazil.
,
Maria Eduarda Nobre de Magalhães Costa 
9   Universidade Federal Fluminense, Rio de Janeiro RJ, Brazil.
24   Universidade Federal do Rio de Janeiro, Rio de Janeiro RJ, Brazil.
,
Mário Fernando Prieto Peres 
25   Hospital Israelita Albert Einstein, Departamento de Neurologia, São Paulo, SP, Brazil.
,
Mauro Eduardo Jurno 
26   Fundação José Bonifácio Lafayette de Andrada, Faculdade de Medicina de Barbacena, Barbacena MG, Brazil.
27   Fundação Hospitalar do Estado de Minas Gerais, Hospital Regional de Barbacena Dr. José Américo, Barbacena MG, Brazil.
,
Patrícia Machado Peixoto 
28   Secretaria de Estado da Saúde do Distrito Federal, Brasília DF, Brazil.
,
Pedro André Kowacs 
29   Instituto de Neurologia de Curitiba, Serviço de Neurologia, Curitiba PR, Brazil.
30   Universidade Federal do Paraná, Complexo Hospital de Clínicas, Serviço de Neurologia, Curitiba PR, Brazil.
,
Pedro Augusto Sampaio Rocha-Filho 
31   Universidade Federal de Pernambuco, Centro de Ciências Médicas, Área de Neuropsquiatria, Recife PE, Brazil.
32   Universidade de Pernambuco, Hospital Universitário Oswaldo Cruz, Ambulatório de Cefaleias, Recife PR, Brazil.
,
Pedro Ferreira Moreira Filho 
33   Universidade Federal Fluminense, Hospital Universitário Antônio Pedro, Departamento de Medicina Clínica, Niterói RJ, Brazil.
,
Raimundo Pereira Silva-Neto 
34   Universidade Federal do Pará, Belém PA, Brazil.
35   Universidade do Estado do Pará, Belém PA, Brazil.
,
Yara Dadalti Fragoso 
36   Universidade Metropolitana de Santos, Santos SP, Brazil.
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Background Migraine affects 1 billion people worldwide and > 30 million Brazilians; besides, it is an underdiagnosed and undertreated disorder.

Objective The need to disseminate knowledge about the prophylactic treatment of migraine is known, so the Brazilian Headache Society (SBCe, in the Portuguese acronym) appointed a committee of authors with the objective of establishing a consensus with recommendations on the prophylactic treatment of episodic migraine based on articles from the world literature as well as from personal experience.

Methods Meetings were held entirely online, with the participation of 12 groups that reviewed and wrote about the pharmacological categories of drugs and, at the end, met to read and finish the document. The drug classes studied in part II of this Consensus were: antihypertensives, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, calcium channel blockers, other drugs, and rational polytherapy.

Results From this list of drugs, only candesartan has been established as effective in controlling episodic migraine. Flunarizine, venlafaxine, duloxetine, and pizotifen were defined as likely to be effective, while lisinopril, enalapril, escitalopram, fluvoxamine, quetiapine, atorvastatin, simvastatin, cyproheptadine, and melatonin were possibly effective in prophylaxis of the disease.

Conclusions Despite an effort by the scientific community to find really effective drugs in the treatment of migraine, given the large number of drugs tested for this purpose, we still have few therapeutic options.

Resumo

Antecedentes Migrânea afeta um bilhão de pessoas em todo o mundo e mais de 30 milhões de brasileiros; além disso, é um distúrbio subdiagnosticado e subtratado.

Objetivo Sabe-se sobre a necessidade de difundir o conhecimento sobre o tratamento profilático da migrânea; por isso, a Sociedade Brasileira de Cefaleias (SBCe) nomeou um comitê de autores com o objetivo de estabelecer um consenso com recomendações sobre o tratamento profilático da migrânea episódica com base em artigos da literatura mundial, assim como da experiência pessoal.

Métodos As reuniões foram realizadas inteiramente online, com a participação de 12 grupos que revisaram e escreveram sobre as categorias farmacológicas dos medicamentos e, ao final, reuniram-se para a leitura e conclusão do documento. As classes de medicamentos estudadas na parte II deste Consenso foram: anti-hipertensivos, inibidores seletivos de recaptação de serotonina, inibidores de recaptação de serotonina e noradrenalina, bloqueadores dos canais de cálcio, outros medicamentos e politerapia racional.

Resultados Desta lista de medicamentos, apenas o candesartan foi estabelecido como eficaz no controle da migrânea episódica. Flunarizina, venlafaxina, duloxetina e pizotifeno foram definidos como provavelmente eficazes, enquanto lisinopril, enalapril, escitalopram, fluvoxamina, quetiapina, atorvastatina, sinvastatina, ciproheptadina e melatonina foram possivelmente eficazes na profilaxia da doença.

Conclusões Apesar do esforço da comunidade científica em encontrar medicamentos realmente eficazes no tratamento da migrânea, dado o grande número de medicamentos testados para este fim, ainda dispomos de poucas opções terapêuticas.

Palavras-chave

Cefaleia Histamínica - Enxaqueca Sem Aura - Consenso - Medicina Preventiva

Keywords

Cluster Headache - Migraine Without Aura - Consensus - Preventive Medicine

Authors' Contributions

PSFS: Discussion, group coordinator, writing, reviewing, conceptualization; EMM, PAK: discussion, group coordinator, writing, reviewing, conceptualization, editing, data collection; AOK, ATNMC, CAPR, EMS, GOMT, IF, LCC, LMB, MFPP, PMP, RPSN, HCC: writing, reviewing, discussion, conceptualization; EJP, JJFC: writing, reviewing, editing, group coordinator, discussion; JAS, LPQ, MNPS: writing, reviewing, editing, discussion; JAJM, JBAS, MENMC: writing, reviewing, discussion; JGS: writing; MRCFF, MEJ, PFMF, YDF: writing, reviewing; Rocha-Filho P. F. M.: conceptualization, data collection, writing, reviewing, editing.




Publikationsverlauf

Eingereicht: 11. Dezember 2021

Angenommen: 09. April 2022

Artikel online veröffentlicht:
18. Oktober 2022

© 2022. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Ripa P, Ornello R, Pistoia F, Carolei A, Sacco S. The renin-angiotensin system: a possible contributor to migraine pathogenesis and prophylaxis. Expert Rev Neurother 2014; 14 (09) 1043-1055
    CrossrefPubMedGoogle Scholar
  • 2 Halker RB, Starling AJ, Vargas BB, Schwedt TJ. ACE and ARB Agents in the Prophylactic Therapy of Migraine-How Effective Are They?. Curr Treat Options Neurol 2016; 18 (04) 15
    CrossrefPubMedGoogle Scholar
  • 3 Tronvik E, Stovner LJ, Bovim G. et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. BMC Neurol 2008; 8: 4 DOI: 10.1186/1471-2377-8-4.
    CrossrefPubMedGoogle Scholar
  • 4 Dorosch T, Ganzer CA, Lin M, Seifan A. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults. Curr Pain Headache Rep 2019; 23 (11) 85
    CrossrefPubMedGoogle Scholar
  • 5 Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322 (7277): 19-22
    CrossrefPubMedGoogle Scholar
  • 6 Sonbolestan SA, Heshmat K, Javanmard SH, Saadatnia M. Efficacy of Enalapril in Migraine Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial. Int J Prev Med 2013; 4 (01) 72-77
    PubMedGoogle Scholar
  • 7 Paterna S, di Pasquale P, Martino S. et al. [Captopril versus placebo in the prevention of hemicrania without aura. A randomized double-blind study]. Clin Ter 1992; 141 (12) 475-481
    PubMedGoogle Scholar
  • 8 Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003; 289 (01) 65-69
    CrossrefPubMedGoogle Scholar
  • 9 Stovner LJ, Linde M, Gravdahl GB. et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 2014; 34 (07) 523-532 DOI: 10.1177/0333102413515348.
    CrossrefPubMedGoogle Scholar
  • 10 Diener HC, Gendolla A, Feuersenger A. et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia 2009; 29 (09) 921-927 DOI: 10.1111/j.1468-2982.2008.01825.x.
    CrossrefPubMedGoogle Scholar
  • 11 Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007; 46 (04) 281-290
    CrossrefPubMedGoogle Scholar
  • 12 Lucas RA. The human pharmacology of fluoxetine. Int J Obes Relat Metab Disord 1992; 16 (Suppl 4): S49-S54
    PubMedGoogle Scholar
  • 13 DeVane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 1992; 53 (Suppl): 13-20
    PubMedGoogle Scholar
  • 14 Pastoor D, Gobburu J. Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol 2014; 10 (01) 121-128 DOI: 10.1517/17425255.2014.863873.
    CrossrefPubMedGoogle Scholar
  • 15 Lexapro FDA. (escitalopram oxalate) Tablets/Oral Solution NDA 21–323/NDA 21–365. Accessed in April 4 th 2020 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021323s032,021365s023lbl.pdf
    Google Scholar
  • 16 Rampello L, Alvano A, Chiechio S. et al. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology 2004; 50 (04) 322-328
    CrossrefPubMedGoogle Scholar
  • 17 Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992; 32 (02) 101-104 DOI: 10.1111/j.1526-4610.1992.hed3202101.x.
    CrossrefPubMedGoogle Scholar
  • 18 Saper JR, Silberstein SD, Lake III AE, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994; 34 (09) 497-502
    CrossrefPubMedGoogle Scholar
  • 19 Steiner TJ, Ahmed F, Findley LJ, MacGregor EA, Wilkinson M. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 1998; 18 (05) 283-286
    CrossrefPubMedGoogle Scholar
  • 20 d'Amato CC, Pizza V, Marmolo T, Giordano E, Alfano V, Nasta A. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 1999; 39 (10) 716-719
    CrossrefPubMedGoogle Scholar
  • 21 Tomkins GE, Jackson JL, O'Malley PG, Balden E, Santoro JE. Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med 2001; 111 (01) 54-63 DOI: 10.1016/s0002-9343(01)00762-8.
    CrossrefPubMedGoogle Scholar
  • 22 Burch R. Antidepressants for Preventive Treatment of Migraine. Curr Treat Options Neurol 2019; Mar 21; 21 (04) 18
    CrossrefPubMedGoogle Scholar
  • 23 Landy S, McGinnis J, Curlin D, Laizure SC. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache 1999; 39 (01) 28-32 DOI: 10.1046/j.1526-4610.1999.3901028.x.
    CrossrefPubMedGoogle Scholar
  • 24 Bánk J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 1994; 34 (08) 476-478 DOI: 10.1111/j.1526-4610.1994.hed3408476.x.
    CrossrefPubMedGoogle Scholar
  • 25 Wellington K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs 2001; 15 (08) 643-669
    CrossrefPubMedGoogle Scholar
  • 26 Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45 (02) 144-152
    CrossrefPubMedGoogle Scholar
  • 27 Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107 (01) 44-48
    CrossrefPubMedGoogle Scholar
  • 28 Wang F, Wang J, Cao Y, Xu Z. Serotonin-norepinephrine reuptake inhibitors for the prevention of migraine and vestibular migraine: a systematic review and meta-analysis. Reg Anesth Pain Med 2020; 45 (05) 323-330 DOI: 10.1136/rapm-2019-101207.
    CrossrefPubMedGoogle Scholar
  • 29 Pergolizzi Jr JV, Raffa RB, Taylor Jr R, Rodriguez G, Nalamachu S, Langley P. A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract 2013; 13 (03) 239-252 DOI: 10.1111/j.1533-2500.2012.00578.x.
    CrossrefPubMedGoogle Scholar
  • 30 Young WB, Bradley KC, Anjum MW, Gebeline-Myers C. Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study. Headache 2013; 53 (09) 1430-1437 DOI: 10.1111/head.12205.
    CrossrefPubMedGoogle Scholar
  • 31 Kisler LB, Weissman-Fogel I, Coghill RC, Sprecher E, Yarnitsky D, Granovsky Y. Individualization of migraine prevention: a randomized controlled trial of psychophysical-based prediction of duloxetine efficacy. Clin J Pain 2019; 35 (09) 753-765 DOI: 10.1097/AJP.0000000000000739.
    CrossrefPubMedGoogle Scholar
  • 32 Louis P. A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache 1981; 21 (06) 235-239
    CrossrefPubMedGoogle Scholar
  • 33 Diamond S, Schenbaum H. Flunarizine, a calcium channel blocker, in the prophylactic treatment of migraine. Headache 1983; 23 (01) 39-42
    CrossrefPubMedGoogle Scholar
  • 34 Gelmers HJ. Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. Headache 1983; 23 (03) 106-109
    CrossrefPubMedGoogle Scholar
  • 35 Amery WK. Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Headache 1983; 23 (02) 70-74
    CrossrefPubMedGoogle Scholar
  • 36 Meyer JS, Hardenberg J. Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches. Headache 1983; 23 (06) 266-277
    CrossrefPubMedGoogle Scholar
  • 37 Meyer JS, Dowell R, Mathew N, Hardenberg J. Clinical and hemodynamic effects during treatment of vascular headaches with verapamil. Headache 1984; 24 (06) 313-321 DOI: 10.1111/j.1526-4610.1984.hed2406313.x.
    CrossrefPubMedGoogle Scholar
  • 38 Micieli G, Sances G, Pacchetti C, Trucco M, Magri M, Piazza D. Flunarizine: a wide spectrum prophylactic for migraine headache. Int J Clin Pharmacol Res 1984; 4 (03) 239-245
    PubMedGoogle Scholar
  • 39 Markley HG, Cheronis JC, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 1984; 34 (07) 973-976
    CrossrefPubMedGoogle Scholar
  • 40 Solomon GD. Verapamil in migraine prophylaxis–a five-year review. Headache 1989; 29 (07) 425-427
    CrossrefPubMedGoogle Scholar
  • 41 Gabai IJ, Spierings ELH. Prophylactic treatment of cluster headache with verapamil. Headache 1989; 29 (03) 167-168
    CrossrefPubMedGoogle Scholar
  • 42 Greenberg DA. Calcium channel antagonists and the treatment of migraine. Clin Neuropharmacol 1986; 9 (04) 311-328
    CrossrefPubMedGoogle Scholar
  • 43 Olesen J. Calcium antagonists in migraine and vertigo. Possible mechanisms of action and review of clinical trials. Eur Neurol 1990; 30 (Suppl. 02) 31-34 , discussion 39–41
    CrossrefPubMedGoogle Scholar
  • 44 Rau JC, Dodick DW. Other Preventive Anti-Migraine Treatments: ACE Inhibitors, ARBs, Calcium Channel Blockers, Serotonin Antagonists, and NMDA Receptor Antagonists. Curr Treat Options Neurol 2019; 21 (04) 17
    CrossrefPubMedGoogle Scholar
  • 45 Peroutka SJ. The pharmacology of calcium channel antagonists: a novel class of anti-migraine agents?. Headache 1983; 23 (06) 278-283
    CrossrefPubMedGoogle Scholar
  • 46 Peroutka SJ, Banghart SB, Allen GS. Relative potency and selectivity of calcium antagonists used in the treatment of migraine. Headache 1984; 24 (02) 55-58
    CrossrefPubMedGoogle Scholar
  • 47 Markley HG. Verapamil and migraine prophylaxis: mechanisms and efficacy. Am J Med 1991; 90 (5A): 48S-53S
    CrossrefPubMedGoogle Scholar
  • 48 Ye Q, Wang Q, Yan LY. et al. Flunarizine inhibits sensory neuron excitability by blocking voltage-gated Na+ and Ca2+ currents in trigeminal ganglion neurons. Chin Med J (Engl) 2011; 124 (17) 2649-2655
    Google Scholar
  • 49 Ye Q, Yan LY, Xue LJ. et al. Flunarizine blocks voltage-gated Na(+) and Ca(2+) currents in cultured rat cortical neurons: A possible locus of action in the prevention of migraine. Neurosci Lett 2011; 487 (03) 394-399
    CrossrefPubMedGoogle Scholar
  • 50 Li F, Qiu E, Dong Z, Liu R, Wu S, Yu S. Protection of flunarizine on cerebral mitochondria injury induced by cortical spreading depression under hypoxic conditions. J Headache Pain 2011; 12 (01) 47-53
    CrossrefPubMedGoogle Scholar
  • 51 Ambrosio C, Stefanini E. Interaction of flunarizine with dopamine D2 and D1 receptors. Eur J Pharmacol 1991; 197 (2-3): 221-223
    CrossrefPubMedGoogle Scholar
  • 52 Mentenopoulos G, Manafi T, Logothetis J, Bostantzopoulou S. Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia 1985; 5 (Suppl. 02) 135-140
    CrossrefPubMedGoogle Scholar
  • 53 Sørensen PS, Hansen K, Olesen J. A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia 1986; 6 (01) 7-14
    CrossrefPubMedGoogle Scholar
  • 54 Paterna S, Martino SG, Campisi D, Cascio Ingurgio N, Marsala BA. [Evaluation of the effects of verapamil, flunarizine, diltiazem, nimodipine and placebo in the prevention of hemicrania. A double-blind randomized cross-over study]. Clin Ter 1990; 134 (02) 119-125
    PubMedGoogle Scholar
  • 55 Thomas M, Behari M, Ahuja GK. Flunarizine in migraine prophylaxis: an Indian trial. Headache 1991; 31 (09) 613-615
    CrossrefPubMedGoogle Scholar
  • 56 al Deeb SM, Biary N, Bahou Y, al Jaberi M, Khoja W. Flunarizine in migraine: a double-blind placebo-controlled study (in a Saudi population). Headache 1992; 32 (09) 461-462
    CrossrefPubMedGoogle Scholar
  • 57 Diamond S, Freitag FG. A double blind trial of flunarizine in migraine prophylaxis. Headache Quart Curr Treatment Res 1993; 4: 169-172
    Google Scholar
  • 58 Gray RN, Goslin RE, McCrory DC, Eberlein K, Tulsky J, Hasselblad V. AHRQ Technical Reviews. Drug treatments for the prevention of migraine headache. Rockville (MD): Agency for Health Care Policy and Research (US); 1999
    Google Scholar
  • 59 Reveiz-Herault L, Cardona AF, Ospina EG, Carrillo P. [Effectiveness of flunarizine in the prophylaxis of migraine: a meta-analytical review of the literature]. Rev Neurol 2003; 36 (10) 907-912
    PubMedGoogle Scholar
  • 60 Jackson JL, Cogbill E, Santana-Davila R. et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One 2015; 10 (07) e0130733 DOI: 10.1371/journal.pone.0130733.
    CrossrefPubMedGoogle Scholar
  • 61 Diener HC, Matias-Guiu J, Hartung E. et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 2002; 22 (03) 209-221
    CrossrefPubMedGoogle Scholar
  • 62 Luo N, Di W, Zhang A. et al. A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Med 2012; 13 (01) 80-86 DOI: 10.1111/j.1526-4637.2011.01295.x.
    CrossrefPubMedGoogle Scholar
  • 63 Lai KL, Niddam DM, Fuh JL. et al. Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. Acta Neurol Scand 2017; 135 (04) 476-483
    CrossrefPubMedGoogle Scholar
  • 64 Sørensen PS, Larsen BH, Rasmussen MJ. et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 1991; 31 (10) 650-657
    CrossrefPubMedGoogle Scholar
  • 65 Lamsudin R, Sadjimin T. Comparison of the efficacy between flunarizine and nifedipine in the prophylaxis of migraine. Headache 1993; 33 (06) 335-338
    CrossrefPubMedGoogle Scholar
  • 66 Mitsikostas DD, Polychronidis I. Valproate versus flunarizine in migraine prophylaxis: a randomized, double-open, clinical trial. Funct Neurol 1997; 12 (05) 267-276
    PubMedGoogle Scholar
  • 67 McArthur JC, Marek K, Pestronk A, McArthur J, Peroutka SJ. Nifedipine in the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side effects. Neurology 1989; 39 (2 Pt 1): 284-286 DOI: 10.1212/wnl.39.2.284.
    CrossrefPubMedGoogle Scholar
  • 68 Shukla R, Garg RK, Nag D, Ahuja RC. Nifedipine in migraine and tension headache: a randomised double blind crossover study. J Assoc Physicians India 1995; 43 (11) 770-772
    PubMedGoogle Scholar
  • 69 Albers GW, Simon LT, Hamik A, Peroutka SJ. Nifedipine versus propranolol for the initial prophylaxis of migraine. Headache 1989; 29 (04) 215-218
    CrossrefPubMedGoogle Scholar
  • 70 Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA 1983; 250 (18) 2500-2502
    CrossrefPubMedGoogle Scholar
  • 71 Brunton LL, Da Fonseca AL, Langeloh A. As bases farmacológicas da terapêutica de Goodman e Gilman. MCGRAW HILL - ARTMED. 2018 https://books.google.com.br/books?id=tmrBvwEACAAJ
    PubMedGoogle Scholar
  • 72 Ryan RE. BC-105 a new preparation for the interval treatment of migraine–a double blind evaluation compared with a placebo. Headache 1971; 11 (01) 6-18 DOI: 10.1111/j.1526-4610.1971.hed110106.x.
    CrossrefPubMedGoogle Scholar
  • 73 Rao BS, Das DG, Taraknath VR, Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India 2000; 48 (03) 223-226
    PubMedGoogle Scholar
  • 74 Carroll JD, Maclay WP. Pizotifen (BC 105) in migraine prophylaxis. Curr Med Res Opin 1975; 3 (02) 68-71 DOI: 10.1185/03007997509113649.
    CrossrefPubMedGoogle Scholar
  • 75 Osterman PO. A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol (Divascan) in migraine prophylaxis. Acta Neurol Scand 1977; 56 (01) 17-28 DOI: 10.1111/j.1600-0404.1977.tb01405.x.
    CrossrefPubMedGoogle Scholar
  • 76 Kangasniemi P. Placebo, 1-isopropylnoradrenochrome-5-monosemicarbazono and pizotifen in migraine prophylaxis. Headache 1979; 19 (04) 219-222 DOI: 10.1111/j.1526-4610.1979.hed1904219.x.
    CrossrefPubMedGoogle Scholar
  • 77 Louis P, Spierings EL. Comparison of flunarizine (Sibelium) and pizotifen (Sandomigran) in migraine treatment: a double-blind study. Cephalalgia 1982; 2 (04) 197-203 DOI: 10.1046/j.1468-2982.1982.0204197.x.
    CrossrefPubMedGoogle Scholar
  • 78 Cerbo R, Casacchia M, Formisano R, Buzzi MG, Boni B, Feliciani M, Grillo G, Cusimano G, Agnoli A. Double-blind clinical study: flunarizine versus pizotifen in a single nightly dose in hemicrania patients. [Article in Italian]. Riv Neurol 1985; Mar-Apr; 55 (02) 139-146
    PubMedGoogle Scholar
  • 79 Cerbo R, Casacchia M, Formisano R. et al. Flunarizine-pizotifen single-dose double-blind cross-over trial in migraine prophylaxis. Cephalalgia 1986; 6 (01) 15-18 DOI: 10.1046/j.1468-2982.1986.0601015.x.
    CrossrefPubMedGoogle Scholar
  • 80 Rascol A, Montastruc JL, Rascol O. Flunarizine versus pizotifen: a double-blind study in the prophylaxis of migraine. Headache 1986; 26 (02) 83-85 DOI: 10.1111/j.1526-4610.1986.hed2602083.x.
    CrossrefPubMedGoogle Scholar
  • 81 Vilming S, Standnes B, Hedman C. Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine. A double-blind investigation. Cephalalgia 1985; 5 (01) 17-23 DOI: 10.1046/j.1468-2982.1985.0501017.x.
    CrossrefPubMedGoogle Scholar
  • 82 Behan PO, Connelly K. Prophylaxis of migraine: a comparison between naproxen sodium and pizotifen. Headache 1986; 26 (05) 237-239 DOI: 10.1111/j.1526-4610.1986.hed2605237.x.
    CrossrefPubMedGoogle Scholar
  • 83 Havanka-Kanniainen H, Hokkanen E, Myllylä VV. Efficacy of nimodipine in comparison with pizotifen in the prophylaxis of migraine. Cephalalgia 1987; 7 (01) 7-13 DOI: 10.1046/j.1468-2982.1987.0701007.x.
    CrossrefPubMedGoogle Scholar
  • 84 Israil A, Ahmed S, Rahman KM. et al. Efficacy of amitriptyline, pizotifen and propranolol in the prevention of migraine. Mymensingh Med J 2013; 22 (01) 93-100
    PubMedGoogle Scholar
  • 85 Mastrosimone F, Iaccarino C, de Caterina G. Efficacy and tolerance of cyclandelate versus pizotifen in the prophylaxis of migraine. J Med 1992; 23 (01) 1-16
    Google Scholar
  • 86 Capildeo R, Rose FC. Single-dose pizotifen, 1.5 mg nocte: a new approach in the prophylaxis of migraine. Headache 1982; 22 (06) 272-275 DOI: 10.1111/j.1526–4610.1982.hed2206272.x.
    CrossrefPubMedGoogle Scholar
  • 87 Cleland PG, Barnes D, Elrington GM, Loizou LA, Rawes GD. Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone. Eur Neurol 1997; 38 (01) 31-38 DOI: 10.1159/000112899.
    CrossrefPubMedGoogle Scholar
  • 88 Wörz R, Drillisch C. [Migraine prevention by a calcium channel blocker. Results of a double-blind study of flunarizine vs. pizotifen]. MMW Munch Med Wochenschr 1983; 125 (32-33): 711-714
    PubMedGoogle Scholar
  • 89 Vogler B, Rapoport AM, Tepper SJ, Sheftell F, Bigal ME. Role of melatonin in the pathophysiology of migraine: implications for treatment. CNS Drugs 2006; 20 (05) 343-350 DOI: 10.2165/00023210-200620050-00001.
    CrossrefPubMedGoogle Scholar
  • 90 Singh M, Jadhav HR. Melatonin: functions and ligands. Drug Discov Today 2014; 19 (09) 1410-1418
    CrossrefPubMedGoogle Scholar
  • 91 Gonçalves AL, Martini Ferreira A, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MF. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry 2016; 87 (10) 1127-1132 DOI: 10.1136/jnnp-2016-313458.
    CrossrefPubMedGoogle Scholar
  • 92 Bredfeldt RC, Sutherland JE, Kruse JE. Efficacy of transdermal clonidine for headache prophylaxis and reduction of narcotic use in migraine patients. A randomized crossover trial. J Fam Pract 1989; 29 (02) 153-156 , discussion 157–158
    Google Scholar
  • 93 Sills M, Congdon P, Forsythe I. Clonidine and childhood migraine: a pilot and double-blind study. Dev Med Child Neurol 1982; 24 (06) 837-841
    PubMedGoogle Scholar
  • 94 Fairbanks CA, Stone LS, Kitto KF, Nguyen HO, Posthumus IJ, Wilcox GL. alpha(2C)-Adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. J Pharmacol Exp Ther 2002; 300 (01) 282-290
    CrossrefPubMedGoogle Scholar
  • 95 Shafar J, Tallett ER, Knowlson PA. Evaluation of clonidine in prophylaxis of migraine. Double-blind trial and follow-up. Lancet 1972; 1 (7747): 403-407
    CrossrefPubMedGoogle Scholar
  • 96 Ryan Sr RE, Diamond S, Ryan Jr RE. Double blind study of clonidine and placebo for the prophylactic treatment of migraine. Headache 1975; 15 (03) 202-210 DOI: 10.1111/j.1526-4610.1975.hed1503202.x.
    CrossrefPubMedGoogle Scholar
  • 97 Sillanpää M. Clonidine prophylaxis of childhood migraine and other vascular headache. A double blind study of 57 children. Headache 1977; 17 (01) 28-31
    CrossrefPubMedGoogle Scholar
  • 98 Stensrud P, Sjaastad O. Clonidine (Catapresan)-double-blind study after long-term treatment with the drug in migraine. Acta Neurol Scand 1976; 53 (03) 233-236
    CrossrefPubMedGoogle Scholar
  • 99 Kallanranta T, Hakkarainen H, Hokkanen E, Tuovinen T. Clonidine in migraine prophylaxis. Headache 1977; 17 (04) 169-172
    CrossrefPubMedGoogle Scholar
  • 100 Mondrup K, Moller CE. Prophylactic treatment of migraine with clonidine. A controlled clinical trial. Acta Neurol Scand 1977; 56 (05) 405-412
    CrossrefPubMedGoogle Scholar
  • 101 Adam EI, Gore SM, Price WH. Double blind trial of clonidine in the treatment of migraine in a general practice. J R Coll Gen Pract 1978; 28 (195) 587-590
    PubMedGoogle Scholar
  • 102 Boisen E, Deth S, Hübbe P, Jansen J, Klee A, Leunbach G. Clonidine in the prophylaxis of migraine. Acta Neurol Scand 1978; 58 (05) 288-295
    CrossrefPubMedGoogle Scholar
  • 103 Das SM, Ahuja GK, Narainaswamy AS. Clonidine in prophylaxis of migraine. Acta Neurol Scand 1979; 60 (04) 214-217
    CrossrefPubMedGoogle Scholar
  • 104 Kåss B, Nestvold K. Propranolol (Inderal) and clonidine (Catapressan) in the prophylactic treatment of migraine. A comparative trial. Acta Neurol Scand 1980; 61 (06) 351-356
    CrossrefPubMedGoogle Scholar
  • 105 Louis P, Schoenen J, Hedman C. Metoprolol v. clonidine in the prophylactic treatment of migraine. Cephalalgia 1985; 5 (03) 159-165
    CrossrefPubMedGoogle Scholar
  • 106 Mascia A, Afra J, Schoenen J. Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data. Cephalalgia 1998; 18 (04) 174-182
    CrossrefPubMedGoogle Scholar
  • 107 Krymchantowski AV, Jevoux C. Quetiapine for the prevention of migraine refractory to the combination of atenolol + nortriptyline + flunarizine: an open pilot study. Arq Neuropsiquiatr 2008; 66 (3B): 615-618 DOI: 10.1590/S0004–282 × 2008000500002.
    CrossrefGoogle Scholar
  • 108 Brandes JL, Roberson SC, Pearlman SH, Abu-Shakra S. Quetiapine for migraine prophylaxis. 44th anual scientific meeting. American Headache Society 2002; Abstract S101. https://doi.org/10.1046/j.1526-4610.2002.t01–1-04250.x
    CrossrefGoogle Scholar
  • 109 LaPorta LD. Relief from migraine headache with aripiprazole treatment. Headache 2007; 47 (06) 922-926
    CrossrefPubMedGoogle Scholar
  • 110 Boeker T. Ziprasidone and migraine headache. Am J Psychiatry 2002; 159 (08) 1435-1436
    CrossrefPubMedGoogle Scholar
  • 111 Nilsson B, Back V, Wei R, Plane F, Jurasz P, Bungard TJ. Potential antimigraine effects of warfarin: An exploration of biological mechanism with survey of patients. TH Open 2019; 3 (02) e180-e189 DOI: 10.1055/s-0039-1692989.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 112 Maggioni F, Bruno M, Mainardi F, Lisotto C, Zanchin G. Migraine responsive to warfarin: an update on anticoagulant possible role in migraine prophylaxis. Neurol Sci 2012; 33 (06) 1447-1449 DOI: 10.1007/s10072-011-0926-4.
    CrossrefPubMedGoogle Scholar
  • 113 Narasimhan P. Letter: Decreased sensitivity to oral anticoagulant therapy after attacks of migraine. Lancet 1974; 2 (7889): 1143 DOI: 10.1016/s0140–6736(74)90905–2.
    CrossrefPubMedGoogle Scholar
  • 114 Suresh CG, Neal D, Coupe MO. Warfarin treatment and migraine. Postgrad Med J 1994; 70 (819) 37-38 DOI: 10.1136/pgmj.70.819.37.
    CrossrefPubMedGoogle Scholar
  • 115 Fragoso YD. Reduction of migraine attacks during the use of warfarin. Headache 1997; 37 (10) 667-668 DOI: 10.1046/j.1526–4610.1997.3710667.x.
    CrossrefPubMedGoogle Scholar
  • 116 Ferrarini G, Malferrari G, Zucco R, Gaddi O, Norina M, Pini LA. High prevalence of patent foramen ovale in migraine with aura. J Headache Pain 2005; 6 (02) 71-76
    CrossrefPubMedGoogle Scholar
  • 117 Russo A, Santi S, Gueraldi D, De Paola M, Zani F, Pini LA. An unusual case report on the possible role of Warfarin in migraine prophylaxis. Springerplus 2013; 2 (01) 48 DOI: 10.1186/2193-1801-2-48.
    CrossrefPubMedGoogle Scholar
  • 118 Maggioni F, Zanchin G, Mainardi F. Warfarin prophylaxis in migraine without aura but not in primary exercise headache. Acta Neurol Belg 2016; 116 (02) 215-216 DOI: 10.1007/s13760-015-0527-8.
    CrossrefPubMedGoogle Scholar
  • 119 Nilsson BG, Bungard TJ. A case of migraine with aura resolving on warfarin but not on apixaban. Headache 2017; 57 (10) 1614-1617 DOI: 10.1111/head.13190.
    CrossrefPubMedGoogle Scholar
  • 120 Beh SC. A case of vestibular migraine resolving on Warfarin and topiramate. Headache 2018; 58 (04) 599-600 DOI: 10.1111/head.13266.
    CrossrefPubMedGoogle Scholar
  • 121 Mohanty S, Mohanty P, Rutledge JN. et al. Effect of catheter ablation and periprocedural anticoagulation regimen on the clinical course of migraine in atrial fibrillation patients with or without pre-existent migraine: results from a prospective study. Circ Arrhythm Electrophysiol 2015; 8 (02) 279-287
    CrossrefPubMedGoogle Scholar
  • 122 Selmaj K, de Belleroche J, Das I, Rose FC. Leukotriene B4 generation by polymorphonuclear leukocytes: possible involvement in the pathogenesis of headache. Headache 1986; 26 (09) 460-464 DOI: 10.1111/j.1526–4610.1986.hed2609460.x.
    CrossrefPubMedGoogle Scholar
  • 123 Gazzaniga PP, Ferroni P, Lenti L. et al. Identification of blood leukotrienes in classical migraine. Headache 1987; 27 (04) 211-215 DOI: 10.1111/j.1526-4610.1987.hed2704211.x.
    CrossrefPubMedGoogle Scholar
  • 124 LaMancusa R, Pulcinelli FM, Ferroni P. et al. Blood leukotrienes in headache: correlation with platelet activity. Headache 1991; 31 (06) 409-414 DOI: 10.1111/j.1526-4610.1991.hed3106409.x.
    CrossrefPubMedGoogle Scholar
  • 125 Riccioni G, Bucciarelli T, Mancini B, Di Ilio C, D'Orazio N. Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem 2007; 14 (18) 1966-1977 DOI: 10.2174/092986707781368522.
    CrossrefPubMedGoogle Scholar
  • 126 Brandes JL, Visser WH, Farmer MV. et al; Protocol 125 study group. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study. Headache 2004; 44 (06) 581-586 DOI: 10.1111/j.1526-4610.2004.446006.x.
    CrossrefPubMedGoogle Scholar
  • 127 Freitag FG, Diamond S, Diamond ML, Urban G. Preventive treatment of migraine headache with rofecoxib and montelukast. In: Proceedings of 10th Congress of the International Headache Society, 2001 Jun 29 to Jul 3, Nova York, USA. Cephalalgia. 2001; 21(4):375–376. P2–118. https://doi.org/10.1046/j.1468-2982.2001.00022.x
    CrossrefGoogle Scholar
  • 128 de Souza Carvalho D, Fragoso YD, Coelho FM, Pereira MM. Asthma plus migraine in childhood and adolescence: prophylactic benefits with leukotriene receptor antagonist. Headache 2002; 42 (10) 1044-1047 DOI: 10.1046/j.1526-4610.2002.02236.x.
    CrossrefPubMedGoogle Scholar
  • 129 Sheftell D, Rapoport AM, Walker B, Gamerman I, Weeks R, Baskin S. Leukotriene (LK) antagonists in the prophylaxis of migraine: a potential role for a new class of agents. ASH Meeting. 1999; 39:381. https://doi.org/10.1111/head.1999.39.5.344
    CrossrefPubMedGoogle Scholar
  • 130 Sheftell F, Rapoport A, Weeks R, Walker B, Gammerman I, Baskin S. Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers. Headache 2000; 40 (02) 158-163 DOI: 10.1046/j.1526-4610.2000.00022.x.
    CrossrefPubMedGoogle Scholar
  • 131 Pearlman EM, Fisher S. Preventive treatment for childhood and adolescent headache: role of once daily montelukast sodium. In: Proceedings of 10th Congress of the International Headache Society, 2001 Jun 29 to Jul 3, Nova York, USA. Cephalalgia. 2001; 21(4):461. P3–O18. https://doi.org/10.1046/j.1468–2982.2001.00028.x
    CrossrefGoogle Scholar
  • 132 Souza Carvalho DS, Fragoso YD, Coelho FM, Pereira MM. Asthma + migraine in childhood and adolescence: prophylactic benefits with leukotriene receptor antanogist. In: Proceedings of 10th Congress of the International Headache Society, 2001 Jun 29 to Jul 3, Nova York, USA. Cephalalgia. 2001; 21(4):375–76. P2–117. https://doi.org/10.1046/j.1468–2982.2001.00022.x
    CrossrefGoogle Scholar
  • 133 Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118
    CrossrefPubMedGoogle Scholar
  • 134 Larose E, Ganz P. Statins and endothelial dysfunction. Semin Vasc Med 2004; 4 (04) 333-346
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 135 Couch JR, Hassanein RS. Platelet aggregability in migraine. Neurology 1977; 27 (09) 843-848 DOI: 10.1212/wnl.27.9.843.
    CrossrefPubMedGoogle Scholar
  • 136 Yetkin E, Turhan H. Is it worthwhile to test statin in migraine?. Headache 2007; 47 (03) 448-450 DOI: 10.1111/j.1526-4610.2007.00738.x.
    CrossrefPubMedGoogle Scholar
  • 137 Yin Z, Fang Y, Ren L. et al. Atorvastatin attenuates NF-kappaB activation in trigeminal nucleus caudalis in a rat model of migraine. Neurosci Lett 2009; 465 (01) 61-65 DOI: 10.1016/j.neulet.2009.08.081.
    CrossrefPubMedGoogle Scholar
  • 138 Hesami O, Sistanizad M, Asadollahzade E, Johari MS, Beladi-Moghadam N, Mazhabdar-Ghashghai H. Comparing the effects of atorvastatin with sodium valproate (Divalproex) on frequência and intensity of frequent migraine headaches: A double-blind randomized controlled study. Clin Neuropharmacol 2018; 41 (03) 94-97 DOI: 10.1097/WNF.0000000000000280.
    CrossrefPubMedGoogle Scholar
  • 139 Medeiros FL, Medeiros PL, Valença MM, Dodick D. Simvastatin for migraine prevention. Headache 2007; 47 (06) 855-856 DOI: 10.1111/j.1526-4610.2007.00824.x.
    CrossrefPubMedGoogle Scholar
  • 140 Buettner C, Nir RR, Bertisch SM. et al. Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial. Ann Neurol 2015; 78 (06) 970-981 DOI: 10.1002/ana.24534.
    CrossrefPubMedGoogle Scholar
  • 141 D'Amico D. Controversies in migraine: monotherapy. Neurol Sci 2012; 33 (Suppl. 01) S141-S145
    CrossrefPubMedGoogle Scholar
  • 142 Prusiński A. Monotherapy or polytherapy in migraine. Neuroepidemiology 1987; 6 (04) 186-189
    CrossrefPubMedGoogle Scholar
  • 143 Casucci G, Villani V, Cologno D, D'Onofrio F. Polytherapy for migraine prophylaxis. Neurol Sci 2012; 33 (Suppl 1): S147-S150
    CrossrefPubMedGoogle Scholar
  • 144 Evans RW, Pascual J, Láinez MJ, Leira R. Bending the rule of monotherapy for migraine prevention?. Headache 2005; 45 (06) 748-750
    CrossrefPubMedGoogle Scholar
  • 145 Krymchantowski AV, Bigal ME. Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach. Expert Rev Neurother 2006; 6 (03) 283-289
    CrossrefPubMedGoogle Scholar
  • 146 Bordini CA, Arruda MA, Ciciarelli MC, Speciali JG. Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. A double-blind trial. Arq Neuropsiquiatr 1997; 55 (3B): 536-541
    CrossrefPubMedGoogle Scholar
  • 147 Pascual J, Leira R, Láinez JM. Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 2003; 23 (10) 961-962
    CrossrefPubMedGoogle Scholar
  • 148 Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg 2008; 110 (10) 979-984
    CrossrefPubMedGoogle Scholar
  • 149 Domingues RB, Silva AL, Domingues SA, Aquino CC, Kuster GW. A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine. Arq Neuropsiquiatr 2009; 67 (04) 973-977
    CrossrefPubMedGoogle Scholar
  • 150 Krymchantowski AV, da Cunha Jevoux C, Bigal ME. Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. J Headache Pain 2012; 13 (01) 53-59 DOI: 10.1007/s10194-011-0395-4.
    CrossrefPubMedGoogle Scholar